Luis Calderón – General Manager, Alexion Mexico
Mexico is improving its regulatory framework for orphan drugs. The general manager of Alexion Mexico explains how the company is working with the authorities to ensure adequate regulation is put…
Alexion is a global biopharmaceutical company that combines groundbreaking science with a steadfast commitment to meeting the needs of patients living with severe, life-threatening and often ultra-rare diseases. Alexion scientists are among the first in the world to unlock the therapeutic potential of inhibiting terminal complement, a group of proteins that play an important role in the body’s immune response and can destroy healthy tissue in certain patients. Alexion discovered and developed Soliris® (eculizumab), a first-in-class terminal complement inhibitor, approved in the United States, Canada, European Union, Australia, and Japan as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH). Alexion is working urgently to investigate Soliris and additional biopharmaceuticals as treatments for patients with other rare and severe diseases, including cancer.
Contact details
Alexion
Paseo de los Tamarindos 90
Torre 1 Piso 6 Oficina A
Col. Bosque de la Lomas, Del. Cuajimalpa,
C.P. 05120, México DF
MEXICO
Tel: +52 (55) 5047 1500
Website: http://alxn.com/
Mexico is improving its regulatory framework for orphan drugs. The general manager of Alexion Mexico explains how the company is working with the authorities to ensure adequate regulation is put…
The current negotiations for the Trans-Pacific Partnership (TPP) provide Mexico with a not-to-be-missed opportunity to review the country’s intellectual property system. The partner of the life science practice of the…
In order to mark its 65th anniversary, the Mexican Association of Pharmaceutical Research Industries (AMIIF) organized on March 25-26, 2015 in Mexico City the Semana de la Innovación, a week…
Vaccination is one of the most important achievements of mankind. The general manager of Sanofi Pasteur Mexico shares the company’s vision behind the decision to choose Mexico as one of…
The Japan-based company is changing into a new Takeda. José Manuel Caamaño, general manager of Takeda Mexico, talks about the transformation process the company is going through to become a…
Mexico is a key market for Ipsen to consolidate its footprint in the Americas. The recently appointed general manager and the medical director of the Mexican affiliate discuss how penetrating…
At Valeant each region has a unique mix of prescription brands, branded generics and OTC products. The general manager for Mexico, Central America, the Caribbean and the Andean region discusses…
Providing logistics to the healthcare industry is part of Bomi’s DNA. The CEO of the Mexican affiliate shares his views about the changing Mexican distribution landscape, the company’s current activities…
Andres Matesanz, general manager of ChemSwiss Mexico, shares his views on the Mexican API industry and its regulations as well as his personal ambitions for the company’s future. You…
Siemens is the only company that covers the entire spectrum of diagnostics. The vice president of the healthcare division for Mesoamerica discusses the recent challenges the Mexican market has posed…
At Leo Pharma it’s not just about skin conditions. It’s about the people living with them. The recently appointed senior director for Latin America discusses the plans of the company…
Mayoly Spindler wants to be an international reference in gastroenterology. The general manger of the Mexican affiliate discusses how Mexico is contributing to this goal by always being one step…
As in human health, innovation is key in the animal health industry. The CEO and second generation at the head of Tornel presents the company’s most important milestones since its establishment…
See our Cookie Privacy Policy Here
